S&P 500   4,544.90
DOW   35,677.02
QQQ   374.10
S&P 500   4,544.90
DOW   35,677.02
QQQ   374.10
S&P 500   4,544.90
DOW   35,677.02
QQQ   374.10
S&P 500   4,544.90
DOW   35,677.02
QQQ   374.10

Certara Stock Forecast, Price & News

-0.44 (-1.14 %)
(As of 10/22/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume223,020 shs
Average Volume675,216 shs
Market Capitalization$6.00 billion
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive CERT News and Ratings via Email

Sign-up to receive the latest news and ratings for Certara and its competitors with MarketBeat's FREE daily newsletter.

Certara logo

About Certara

Certara Inc. provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinincal and clinical research, regulatory submissions, and market access. It offers medicines to patients using biosimulation software and technology to transform drug discovery and development. The company also provides related technology-enabled services to guide its customers' new drugs through the regulatory submission process and into the market. Its technology-enabled services include mechanistic biosimulation, empirical biosimulation, drug development and regulatory strategy, clinical pharmacology, model-based meta-analysis, regulatory writing and medical communications, regulatory operations, and market access. The company serves biopharmaceutical companies, and academic and government institutions. It has operations in the United States, Canada, Spain, Luxembourg, Portugal, the United Kingdom, Germany, France, the Netherlands, Denmark, Switzerland, Italy, Poland, Japan, the Philippines, India, and Australia. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.


See More Headlines

Industry, Sector and Symbol

Prepackaged software
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$243.53 million
Cash Flow
$0.01 per share
Book Value
$5.37 per share


Net Income
$-49.40 million




Market Cap
$6.00 billion
Next Earnings Date
11/9/2021 (Confirmed)
Not Optionable


Overall MarketRank

1.55 out of 5 stars

Medical Sector

1027th out of 1,359 stocks

Prepackaged Software Industry

200th out of 258 stocks

Analyst Opinion: 1.3Community Rank: 3.7Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 1.9 5 -4 -3 -2 -1 -

Certara (NASDAQ:CERT) Frequently Asked Questions

Is Certara a buy right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Certara in the last twelve months. There are currently 3 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Certara stock.
View analyst ratings for Certara
or view top-rated stocks.

What stocks does MarketBeat like better than Certara?

Wall Street analysts have given Certara a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Certara wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Certara?

Certara saw a increase in short interest in the month of September. As of September 30th, there was short interest totaling 2,760,000 shares, an increase of 29.6% from the September 15th total of 2,130,000 shares. Based on an average trading volume of 896,200 shares, the days-to-cover ratio is currently 3.1 days. Currently, 3.2% of the shares of the company are sold short.
View Certara's Short Interest

When is Certara's next earnings date?

Certara is scheduled to release its next quarterly earnings announcement on Tuesday, November 9th 2021.
View our earnings forecast for Certara

How can I listen to Certara's earnings call?

Certara will be holding an earnings conference call on Tuesday, November 9th at 5:00 PM Eastern. Interested parties can register for or listen to the call using this link.

How were Certara's earnings last quarter?

Certara, Inc. (NASDAQ:CERT) released its quarterly earnings results on Thursday, August, 5th. The company reported $0.03 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.05 by $0.02. The firm earned $70.10 million during the quarter, compared to analyst estimates of $68.69 million.
View Certara's earnings history

What guidance has Certara issued on next quarter's earnings?

Certara updated its FY 2021 earnings guidance on Thursday, September, 2nd. The company provided earnings per share guidance of $0.210-$0.250 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.220. The company issued revenue guidance of $283 million-$289 million, compared to the consensus revenue estimate of $283.09 million.

What price target have analysts set for CERT?

7 equities research analysts have issued 1-year target prices for Certara's stock. Their forecasts range from $33.00 to $41.00. On average, they expect Certara's stock price to reach $36.33 in the next year. This suggests that the stock has a possible downside of 4.7%.
View analysts' price targets for Certara
or view top-rated stocks among Wall Street analysts.

Who are Certara's key executives?

Certara's management team includes the following people:
  • Dr. William F. Feehery, CEO & Director (Age 50, Pay $1.39M) (LinkedIn Profile)
  • Mr. M. Andrew Schemick, Chief Financial Officer (Age 47, Pay $607.21k)
  • Mr. Leif E. Pedersen, Pres of Software (Age 56, Pay $295.4k)
  • Mr. Andrew Schemick, Chief Financial Officer
  • Prof. Amin Rostami PharmD, Ph.D., FCP, Chief Scientific Officer
  • Mr. Richard M. Traynor, Sr. VP & Gen. Counsel (Age 50) (LinkedIn Profile)
  • Mr. Mark Hovde, Sr. VP of Strategy & Corp. Devel. (Age 64)
  • Ms. Jieun W. Choe, Chief Strategy & Marketing Officer (Age 47) (LinkedIn Profile)
  • Mr. Jaap Mandema, Chief Innovation Officer
  • Dr. Iain Gardner Bpharm, Ph.D., Head of Translational Science and Sr. Scientific Advisor

When did Certara IPO?

(CERT) raised $500 million in an initial public offering (IPO) on Friday, December 11th 2020. The company issued 24,400,000 shares at a price of $19.00-$22.00 per share. Jefferies, Morgan Stanley, BofA Securities, Credit Suisse, Barclays and William Blair acted as the underwriters for the IPO.

What is Certara's stock symbol?

Certara trades on the NASDAQ under the ticker symbol "CERT."

Who are Certara's major shareholders?

Certara's stock is owned by many different institutional and retail investors. Top institutional investors include Baillie Gifford & Co. (8.04%), DekaBank Deutsche Girozentrale (0.03%) and Fifth Third Bancorp (0.00%). Company insiders that own Certara stock include Avatar Parent LP Eqt, Craig R Rayner, Jieun W Choe, Justin Edge, Mason P Slaine, Michael Andrew Schemick, Richard M Traynor, Robert Aspbury and William F Feehery.
View institutional ownership trends for Certara

Which institutional investors are buying Certara stock?

CERT stock was acquired by a variety of institutional investors in the last quarter, including Baillie Gifford & Co., DekaBank Deutsche Girozentrale, and Fifth Third Bancorp.
View insider buying and selling activity for Certara
or or view top insider-buying stocks.

How do I buy shares of Certara?

Shares of CERT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Certara's stock price today?

One share of CERT stock can currently be purchased for approximately $38.13.

How much money does Certara make?

Certara has a market capitalization of $6.00 billion and generates $243.53 million in revenue each year. The company earns $-49.40 million in net income (profit) each year or ($0.32) on an earnings per share basis.

How many employees does Certara have?

Certara employs 300 workers across the globe.

What is Certara's official website?

The official website for Certara is www.certara.com.

Where are Certara's headquarters?

How can I contact Certara?

Certara's mailing address is 100 OVERLOOK CENTER SUITE 101, PRINCETON NJ, 08540. The company can be reached via phone at 609-716-7900.

This page was last updated on 10/25/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.